The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection.
The strong association of HCV infection with MC-II and the selective concentration of the virus with the WA mRF in the cryoglobulins are compelling suggestions that the virus is directly involved in production of the mRF and the pathophysiology of MC-II. There is, however, only limited data on HCV involvement in both processes. In cutaneous vasculitis, which is the most prevalent clinical feature of the disease, there is evidence that complexes of HCV, mRF and IgG are formed in situ from components of the cryoglobulins that are present in the blood in a dissociated state. It is postulated that local factors, cooling and stasis predispose to formation of these lesions in the lower limbs. However, since cutaneous vasculitis does not correlate with cryoglobulin levels and may not be induced by cold challenge, other factors may be involved. In particular, the conditions which activate the vascular endothelial cells, leading to the leukocytoclastic vasculitis, require delineation. In contrast to cutaneous vasculitis, HCV RNA has not been prominently detected in immune complexes in MPGN lesions and has not been detected at all in the peripheral neuropathy lesions. These preliminary observations suggest that different pathophysiological processes are involved in for these lesions than in cutaneous vasculitis. From the correlation of remission of disease with decreased cryoglobulinemia and viremia in treated patients with MC-II, and from immunohistological data on the hepatitic lymphoid follicles in MC-II (see chapter 7), it appears that an antigen-driven benign proliferation of B cells is responsible for production off mRF and cryoglobulinemia. New findings have suggested that one mechanism for developing mixed cryoglobulinemia may be that HCV-VLDL complexes that contain apo E2 are poorly endocytosed by the LDLR, which may be a major route of entry of the virus to the cell; persistence of the complexes in the circulation may then stimulate mRF production. This new hypothesis is based only on initial in vitro observations and require independent confirmation and validation in vivo. From indirect clinical evidence it has also been postulated that mRF in some patients may limit the cytopathology in MC-II, resulting in a lower prevalence of cirrhosis in these patients. These findings suggested another hypothesis, which is that the mRF prevents spread of infection to hepatocytes and other permissive and nonpermissive cells by blocking endocytosis of HCV-VLDL complexes by the LDLR. Furthermore, data on the composition of cryoglobulins, the molecular composition of WA mRF and the characterization of monoclonal B cells in the liver of patients with MC-II (see chapter 7) suggest that a specific population of B cells may be involved in the host response to HCV infection. These are B cells that proliferate with little or no somatic mutations of the immunoglobulin genes, are self-replicating, are stimulated by self antigens in a T cell-independent manner and bear the CD5 marker. The proliferation of this B cell population may be the host's response to the attempt by the virus to circumvent the immune response by complexing with host lipoproteins. It is proposed that HCV complexed to VLDL is the antigen that directly stimulates the proliferation of these primordial type B cells. Testing of these hypotheses may produce insights not only into the etiology of mixed cryoglobulinemia but possibly into the mechanisms by which HCV circumvents the immune response and established chronic infection.
Agnello
V
V
Lahey Hitchcock Clinic, Burlington, MA 01805, USA.
D000911:Antibodies, Monoclonal; D001853:Bone Marrow / Q000276:immunology; D003429:Cross Reactions; D003449:Cryoglobulinemia / Q000209:etiology* / Q000276:immunology / Q000503:physiopathology*; D005838:Genotype; D015432:Glomerulonephritis, Membranoproliferative / Q000209:etiology; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology / Q000472:pathogenicity; D006526:Hepatitis C / Q000150:complications* / Q000276:immunology; D006801:Humans; D007130:Immunoglobulin Idiotypes; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008221:Lymphoid Tissue / Q000276:immunology; D008954:Models, Biological; D010523:Peripheral Nervous System Diseases / Q000209:etiology; D012217:Rheumatoid Factor; D014657:Vasculitis / Q000209:etiology
D000911:Antibodies, Monoclonal; D007130:Immunoglobulin Idiotypes; D008079:Lipoproteins, VLDL; D012217:Rheumatoid Factor